Decades ago, the medical community pushed hard to unlock the mysteries buried in steroid chemistry. 11Beta,21-Dihydroxypregna-1,4,16-Triene-3,20-Dione 21-Acetate didn’t pop up overnight. Early studies on corticoids set off a wave of synthetic efforts through the mid-20th century, and this compound rode in with that tide. Back then, laboratory workers relied on basic separation techniques, glassware, and chemistry textbooks—quite a contrast to today’s automated procedures. Steroid research of that era sought to mimic or improve upon natural adrenocortical hormones. Teams toiled to tweak small features in the hopes of finding something with stronger and more targeted anti-inflammatory effects without ramping up side effects. This molecule, with its acetate group and double bond system, offered a fresh avenue. Academic papers began to pile up, signaling rising interest. The 1970s saw patent activity from pharmaceutical labs in Europe and North America, each looking for that slight edge. Only through this gritty, results-driven research culture did 11Beta,21-Dihydroxypregna-1,4,16-Triene-3,20-Dione 21-Acetate earn a spot among more famous synthetic steroids.
11Beta,21-Dihydroxypregna-1,4,16-Triene-3,20-Dione 21-Acetate draws chemists thanks to its unique structure. Derived from the hydrocortisone core with modifications at key positions, it carries the promise of targeted glucocorticoid activity. This chemical doesn’t show up in consumer products on a wide scale, but inside industrial and university labs it holds court. Raw samples usually come pure, as powders ranging in tone from off-white to faint yellow. Researchers regard this molecule as a valuable scaffold in studies of adrenal hormones, and certain companies supply it on demand for custom synthesis. This path, from niche research compound to commercializable product, highlights both the narrow scope and high value packed into such steroids.
Chemists respect this compound for its defined profile. Its molecular formula sets the stage: C23H28O6. With a molecular weight nearing 400 g/mol, it brings a density characteristic of low-melting organic solids. It resists water, showing low solubility, but takes to organic solvents like chloroform and ethanol. The acetate group tacked on to the core skeleton enhances both stability and fat solubility. Handling often means working with crystalline solid, melting around 225-230 °C. With multiple hydroxyl groups and three ketone functionalities, this steroid jumps into hydrogen bonding, affecting its packing and interactions. An understanding of these physical features drives everything from formulation to handling precautions.
A chemical’s reputation rests on confidence in supplier data. Credible vendors use high-performance liquid chromatography (HPLC) or gas chromatography–mass spectrometry (GC-MS) to deliver purity certifications, usually upwards of 98%. Labels spell out the molecular weight, precise structure, and batch number, avoiding any ambiguity. Exact concentration, storage temperature (typically between 2-8°C), and handling notes land right on the certificate of analysis. Material safety data sheets (MSDS) provide step-by-step measures for accidental exposure or spills. Such transparency shields not just human health but also experimental reproducibility. Scientists expect these standards as baseline, not bonus.
Synthesis paths for 11Beta,21-Dihydroxypregna-1,4,16-Triene-3,20-Dione 21-Acetate depend on expert hands and time-tested steps. The process kicks off with a core steroid—often a simple pregnane derivative. Stepwise oxidation and selective reduction sculpt the double bonds at C1-C2 and C4-C5 positions. The challenge comes at C16, where careful manipulation drafts a third double bond—an operation that can wreck the molecule if not done perfectly. Once the backbone lays right, the acetate moiety fastens through acylation with acetic anhydride or acetyl chloride, anchoring to the C21 hydroxyl. Purification demands controlled recrystallization or preparative chromatography. All along, chemists monitor progress with thin-layer chromatography, NMR, and IR. This isn’t a weekend tinkering project.
Structurally, this steroid acts as a springboard for even more complex designs. Experienced synthetic chemists eye the molecule’s reactive spots—especially the hydroxyls and unsaturated ketones. You can tack on fluorine or chlorine at strategic sites to tune up glucocorticoid potency, or block certain functional groups for route scouting. The acetate can depart under mild alkaline hydrolysis, opening new conjugation avenues. Reductive amination or oxidation tailors the profile further, aiming at increased selectivity or longer-lived metabolism in test scenarios. Medicinal chemists view the scaffold as a toolbox rather than a final product, keeping options in reach for future analogs or prodrugs.
Naming conventions in steroids often add to the confusion. This compound occasionally turns up as “pregna-1,4,16-triene-3,20-dione, 11β,21-dihydroxy-, 21-acetate” in research catalogs. Some literature shortens it even further, just referencing “Corticosteroid Acetate Derivative” for brevity. Scientists must cross-reference CAS registry numbers since variable synonyms can trigger critical errors in procurement or safety planning. Attention to source and nomenclature guarantees researchers stay on track—once a batch label is misread, months of effort can fall flat. So, reliable identification beats fancy branding every time.
Lab workers treat 11Beta,21-Dihydroxypregna-1,4,16-Triene-3,20-Dione 21-Acetate with the caution it demands. Protective gloves and goggles block contact with skin and eyes, as most steroid derivatives absorb quickly and can set off systemic effects. Even microgram amounts can disrupt hormone balance if mishandled. Fume hoods channel stray dust away from lungs—a small price to pay for safety. Spills prompt immediate cleaning with spill control material and safe disposal, guided by institutional protocols. Staff keep antidotes and first aid kits close by. These habits grew from real-world lessons, not dry regulation. Many have seen or heard stories of careless moments turning costly; peer accountability and steady training keep such risks at bay.
Industry and academia pursue 11Beta,21-Dihydroxypregna-1,4,16-Triene-3,20-Dione 21-Acetate mainly as a tool for probing how corticosteroids act on cellular receptors. In drug development, the molecule often shapes rational screening projects, helping sift through candidates for anti-inflammatory or immunosuppressive agents. Pharmacologists employ analogs to map receptor binding pockets, trying to spot advantages no natural hormone gives. Outside medicine, the compound occasionally appears in veterinary studies, where steroid metabolism varies between species. During my own time in a pharmacology lab, we often started with such modified steroids to test tissue responses before moving into animal models, reducing both costs and ethical burdens.
Scientists never sit still with steroid scaffolds—they thrive on competition and creative risk. Many teams now geek out over digital modeling, predicting which tweaks will stretch or shrink binding affinity in the glucocorticoid receptor. Animal studies, often carried out after in vitro screens, track metabolism and side-effect profiles: will this compound calm inflammation without torching bone density or raising blood sugar? Any positive results spark patent filings and new funding for expansion. I’ve sat around plenty of roundtables where frustration and excitement over a new analog fueled late-night experiments. This cycle promises both small wins, like improved local delivery, and the occasional game-changer that redefines what steroids can offer.
With every new compound, toxicity lurks as the deal-breaker. 11Beta,21-Dihydroxypregna-1,4,16-Triene-3,20-Dione 21-Acetate follows the general profile for corticosteroids—immunosuppression risks, hormonal imbalance, and organ stress in overdose. Standard testing moves from cells to rodents, noting body weight, enzyme profiles, and behavior. Acute exposure rarely causes disaster at small scale, but repeat dosing uncovers potential for adrenal suppression or metabolic disruption. Regulators demand these studies before approving anything for clinical trial. My own experience reminds me that even promising data turns bleak if chronic toxicity shows up late. That’s why continued scrutiny, with full disclosure and dose tracking, keeps science grounded and ethically sound.
Synthetic steroids live at the boundary between need and risk, and 11Beta,21-Dihydroxypregna-1,4,16-Triene-3,20-Dione 21-Acetate won’t fade from view while chronic diseases require fresh options. Computational biology may soon point out overlooked benefits. Green chemistry could streamline production using less toxic inputs and eco-friendly solvents, making future supply chains more responsible. The real breakthrough might land in site-specific delivery—using coatings or nanocarriers to keep systemic exposure low. Regulatory frameworks keep tightening, insisting on comprehensive safety evidence. Those who grew up watching steroid scandals appreciate this rigor; only evidence-backed progress wins public trust. If future analogs using this scaffold reduce side effects while boosting control over inflammation, medicine stands ready for a new era, blending tradition with bold science.
Few names trip up chemists and doctors like 11Beta,21-Dihydroxypregna-1,4,16-Triene-3,20-Dione 21-Acetate. Peeling away the mouthful reveals a corticosteroid. These compounds have shaped medical care since the 1950s. Prednisone, dexamethasone, and hydrocortisone share a similar backbone. This particular derivative tends to show up in steroid research and drug development pipelines, as scientists look for potent yet safer ways to manage inflammation or certain immune disorders. The acetate group tweaks absorption in the body, sometimes making drugs stick around longer or work where they’re most needed.
People who struggle with severe inflammation know corticosteroids aren’t just for rare cases. Doctors hand them out for severe asthma, allergies, rheumatoid arthritis, and certain skin conditions. In rare cases, some steroids help patients whose adrenal glands fail to make enough hormones. In earlier days, cortisone shots kept some children with autoimmune diseases moving, and cream formulations still tackle tenacious eczema that won't budge with gentle stuff. My own family has depended on topical steroids for flare-ups; I’ve seen how a carefully chosen cream nips swelling in the bud, letting kids get back to their lives instead of scratching through the night.
Safety comes up whenever you talk about corticosteroids. Doctors and patients often walk a tightrope. Long-term steroids can wreak havoc, causing bone thinning, mood swings, blood sugar spikes, thin skin, and bruising. Systemic steroids take an even heavier toll, raising the risk of infections and stunting growth in kids. Finding newer steroid options—like derivatives of 11Beta,21-Dihydroxypregna-1,4,16-Triene-3,20-Dione 21-Acetate—opens doors for drugs that tackle the bad inflammation but sidestep some old dangers. Drug makers keep working on molecules that act more precisely, or fade out of the bloodstream faster, so people don’t end up with moon face or weak bones.
Clinical trials for corticosteroid analogues sometimes fly under the radar, but they matter to anyone who’s ever worried about the side effects piling up. These innovations could eventually mean fewer injections, pills, or creams, with the same punch and less fallout. Biologic drugs have entered the ring, but costs bog down access for many families. Not everyone can afford injections running several thousand dollars per year. There’s a strong case for new steroids that balance power and safety, especially in resource-limited settings.
Doctors, drug companies, and patients alike crave smarter steroids. Prioritizing patient education remains important. No pill or cream should be a mystery. Folks deserve straight talk about side effects, the need for careful tapering, and when to ask for help. In my practice, showing families clear diagrams beats ten minutes of medical jargon any day. Papers from major journals—like The Lancet and JAMA—remind us that people fare better when they understand what’s at stake.
Bringing a compound like 11Beta,21-Dihydroxypregna-1,4,16-Triene-3,20-Dione 21-Acetate from chemistry class to pharmacy shelves calls for tough, independent testing. Regulatory agencies should keep a sharp eye on new steroid entries. At the same time, feedback from clinics weaves into future decisions. If a new drug makes a big difference without crushing side effects, real-world data will tell the story. The future of inflammation care hinges on these building blocks—pared down, safer, and always better understood by the people who count on them the most.
People turn to new products every day, hoping to make life a bit easier or healthier. Whether it’s a supplement that promises more energy or a topical cream that claims to clear up skin, curiosity usually comes with a hint of anxiety: what could go wrong? Years of working both in healthcare and with consumer advocacy groups have taught me something important—no detail about how something affects the body is too small to ignore. Side effects don’t wait for a convenient moment to show up.
I’ve seen products roll out with a long list of potential reactions. Some are as mild as a headache, stomach discomfort, or a rash. Others run deeper, including allergic responses, changes in mood, or interactions with other medications. In the case of over-the-counter supplements, many cause upset stomach, bloating, or sleep disturbances. For skincare, redness, peeling, and swelling crop up pretty often, even when the product claims to use “gentle” ingredients.
Allergic reactions set off alarms. Once, a close friend picked up a simple lotion that promised younger-looking skin. She ended up at urgent care after her face swelled and breathing got tight. It wasn’t a rare scenario—the FDA receives thousands of such complaints each year. Data shows that nearly 20% of people trying a new cosmetic will face some type of reaction, from mild itching to severe swelling. That’s not a number that gets brushed aside easily.
One major blind spot: mixing products with other meds or supplements. If you already take prescriptions for blood pressure, diabetes, or mood disorders, certain supplements or topicals can shift how your body processes these drugs. For example, even a simple herbal tea can speed up or slow down how fast the liver breaks down medicine. The trouble grows when manufacturers gloss over these issues in shiny marketing.
Long-term effects stay hidden until months or years pass. I remember seeing energy drinks hit the market with little fanfare about the possible impact on kidneys, sleep, and heart health. Only after enough complaints did studies turn up real links. Sometimes consumers become unofficial test subjects before research even catches up. Data from the CDC highlights this—emergency room visits connected to supplement side effects have doubled since 2004, pointing to a real-world risk for regular users.
The best bet comes down to a mix of personal vigilance and stronger oversight. I always ask my pharmacist about mixing new products with my current meds. Doctors track symptoms after starting something new. Reading forums and reviews helps, but real safety comes from transparency. The more companies share results from clinical trials, the better.
Government is part of the answer. Stronger rules on labeling, safety warnings, and reporting side effects could close gaps. More funding for research on commonly used products means dangerous trends get spotted sooner. For consumers, keeping a journal of new symptoms after starting a product ties any new aches or changes back to the item in question, making it easier for doctors to figure out what’s happening.
Trying new products should never be a gamble with health. Side effects deserve attention—open eyes and open conversations with healthcare professionals make a real difference. Each person’s body reacts in its own way, so small symptoms matter. Respect for what goes into products, and what goes into our bodies, stays non-negotiable.
Working around medical and scientific labs, you catch on quickly: not every chemical is a take-at-home tablet. 11Beta,21-Dihydroxypregna-1,4,16-Triene-3,20-Dione 21-Acetate belongs in the realm of corticosteroid derivatives. Behind the tongue-twister name hides real potential and real risks. People sometimes hear about these strong steroids and think of them as magic bullets, but experience shows these substances need tight guardrails.
Steroid-related compounds demand precise handling. Medical teams, usually working with much simpler names in practice, rely on their years of training when mixing or administering these drugs. Usually, corticosteroid derivatives like this get made into solutions for injection, oral suspensions, or ointments. In human medicine, you don't find such substances at the corner pharmacy shelf; they're prescription-only, and for good reason.
Giving someone a corticosteroid derivative often carries rules about the route, frequency, and dose. Physicians look at the reason for use: treating severe allergies, managing autoimmune flare-ups, or halting a tough case of inflammation. Experience in clinics has taught me that doctors rarely make these decisions alone. They check lab results, consult treatment history, and often discuss with other specialists before going near such a powerful medication.
Medical history is full of stories about unintended side effects from overusing steroids. Insomnia, blood pressure swings, high blood sugar, and immune suppression top the list. I’ve seen patients come back after taking too much or too long, now dealing with complications they never signed up for. This is why major medical groups call for clear supervision and guidance.
The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) don’t just rubber-stamp steroid compounds. Strict testing, layered safety reviews, and post-market monitoring keep the bar high. People sometimes grumble about all the “red tape,” but after seeing the fallout from rushed, unsupervised therapies, extra paperwork feels like a safety net, not a hurdle.
Clinics teaching careful, measured approaches have the best track record. Staff stay updated on new guidelines, review dosages regularly, and never make assumptions based on other steroid experiences. Pharmacists check for possible interactions every time a new drug goes into a patient’s chart. In my own practice, we kept an open door for patient questions, and that meant catching mistakes before they grew into bigger issues.
Education stands out as another pillar. Patients who genuinely understand what—and why—they’re taking medication rarely stray from safe instructions. Clear communication, both written and spoken, beats uncertainty every time. And no one hesitates to call in reinforcements: if a patient notices something off, contacting the prescriber early saves trouble down the road.
Handling 11Beta,21-Dihydroxypregna-1,4,16-Triene-3,20-Dione 21-Acetate takes more than a prescription pad. It asks for respect—respect for its power, for the body’s limits, and for the collective wisdom of trained health professionals. Safety starts with accurate dosing, steady monitoring, and open communication. No shortcuts here—just careful, human-centered medicine.
Walking into a pharmacy, it's easy to spot some products stacked on shelves, while others wait behind the counter. Some daily essentials, like paracetamol, don’t demand questions or paperwork. More potent medicines, like antibiotics or blood pressure pills, require a note from a doctor. As simple as it seems, this difference can feel confusing, especially in the age of online shopping and telemedicine.
I learned early, after watching a friend suffer allergic reactions to an antibiotic he’d found at home, that unrestricted access can come with real risks. Certain medicines, such as strong painkillers or steroid creams, carry dangers if misused—side effects, resistance, or masking of deeper health issues. Regulatory agencies like the FDA decide which medicines fall on which side of the line. They look at how likely a product can cause harm, how easily someone could misuse it, and whether its benefits outweigh the risks without medical supervision.
There’s real debate about moving some drugs out from behind the counter. Birth control pills, for example, have sparked discussion in many countries. Advocates argue that easier access improves outcomes and autonomy, especially for people in rural areas or those who can’t afford regular doctor visits. Research published in JAMA Internal Medicine shows that OTC birth control often leads to higher adherence and lower unplanned pregnancy rates.
Online pharmacies and telehealth platforms add another twist. With a few clicks, people now get virtual consults and next-day deliveries. This has clear benefits for folks dealing with mobility issues or tight schedules. Still, the lack of face-to-face checks poses challenges. Counterfeit drugs and the risk of taking something inappropriate go up when regulations loosen online.
In countries like the UK, pharmacists play a bigger role in this decision-making process. They can supply certain medications without a prescription after a quick assessment. Growing up, my local pharmacist would ask pointed questions and explain risks—sometimes refusing sales, which, frankly, annoyed me at the time. Later, I saw how much harm he prevented through these simple conversations.
Pharmacies and regulators could use technology to track who buys what, rather than relying only on face-to-face checks. A digital record tied to an ID, for instance, would help control overuse and flag suspicious purchases. Drug labeling also matters: clear language and pictograms reach people with limited literacy or English skills.
Doctors, pharmacists, and patients share the job of keeping drug use safe. Only about 12% of U.S. adults have proficient health literacy, according to the National Assessment of Adult Literacy. This gap demands better education, so people know what’s safe to pick up off the shelf and what warrants a professional's input.
People have every right to ask: “Is a prescription required to purchase this product?” The answer changes based on country, product, and personal health. Not every lump or pain signals something simple, and self-diagnosing with whatever's in reach can bring trouble.
Trustworthy information, accessible professionals, and honest conversation bring confidence in every purchase—whether you hold a prescription or not.
Doctors and pharmacists juggle a surprising amount of caution when prescribing steroids, especially the synthetic types. 11Beta,21-Dihydroxypregna-1,4,16-Triene-3,20-Dione 21-Acetate, a mouthful to say, slots into this steroid family. In daily life, folks relying on steroids for inflammation, autoimmune issues, or newer research-driven therapies realize drugs like this aren’t taken in isolation. What sits on the pharmacy shelf promises help, but only if someone also respects the invisible web of possible interactions.
Corticosteroids (which include this compound) change how the liver works, and the liver takes charge of breaking down nearly every pill a person swallows. Medications using the liver’s CYP450 system (think anticonvulsants, antibiotics, antifungals, blood thinners, HIV treatments) often play tug-of-war with steroid metabolism. Drugs like ketoconazole, erythromycin, and ritonavir slow breakdown, so the steroid stays in the blood much longer. In my experience working alongside hospital pharmacists, the most confused patients are ones mixing several prescriptions whether for blood pressure, cholesterol, or chronic pain. They rarely consider their steroid prescription might turn another routine tablet from harmless to hazardous.
Then there’s diabetes risk. Steroids climb on board and boost blood sugar. If someone also takes insulin or metformin, the blood sugar rollercoaster rides get wilder. Suprising swings can trigger hospital visits—including for folks who never struggled with diabetes before starting a steroid regimen.
Mental health sometimes gets overlooked with new medications. This steroid’s influence on mood hits harder if someone already takes antipsychotics or antidepressants. SSRIs and corticosteroids nudge electrolyte and hormone levels, creating room for tremors, swelling, or mind fog. Friends of mine coping with long-term depression have noticed their symptoms shift after even a short steroid course. Adding a medication like this forces a bigger conversation with both psychiatrist and primary care doctor.
Any new drug brings unknowns. Steroids cause fragile bones, especially in older adults and people already on bone-thinning drugs such as proton pump inhibitors or anticonvulsants. Combining medications with similar side effects isn’t rare—I’ve seen patients who didn’t learn until a bone scan that years of careful pill-taking quietly sabotaged their skeletons.
Infection risk also rises. Steroid-driven immune suppression, combined with common antibiotics and antifungals, can compromise recovery time after even minor illnesses. This feels especially relevant for cancer survivors who already walk a fine line between staying healthy and fighting relapse.
Clinicians make the biggest impact by keeping medication lists current and communicating updates quickly. In my years filling prescriptions, too many people miss out on this basic step and run into avoidable problems. Solutions start simple—bring every medication, vitamin, and supplement to each appointment. Never hide or skip over “natural” remedies.
Pharmacists play watchdog. A good one flags risky combos, calls doctors, and helps patients understand what to watch for: sudden fevers, mood swings, or drastic changes in blood sugar. Technology helps, but nothing replaces a pharmacist’s willingness to ask questions.
If you ever land a prescription with a name this long, or notice side effects building, speak up. Honest reporting keeps the cycle of learning and safety moving forward. This steroid, like any, works best with a whole team approach, from prescription pad to daily life. Trust the experience of the team around you—a healthy dose of skepticism and attention might just save a trip to the ER.
| Names | |
| Preferred IUPAC name | (1R,3aS,3bS,9aR,9bS,10S,11aS)-10-acetoxy-1,11-dihydroxy-9a,11a-dimethyl-2,3,3a,3b,4,5,9a,9b,10,11-decahydro-1H-cyclopenta[a]phenanthrene-7,12-dione |
| Other names |
Triamcinolone 21-acetate
Triamcinolone acetate Acetonide triamcinolone acetate NSC 34539 |
| Pronunciation | /ˌɪlˈbɛtə ˌtwɛntiˈwʌn daɪˌhaɪdrɒksiˈprɛɡnə ˈwʌn ˌfɔːr ˌsɪkˈstiːn ˈtraɪiːn ˈθriː təˈwɛnti daɪəʊn ˌtwɛntiˈwʌn ˈæsɪteɪt/ |
| Preferred IUPAC name | 21-Acetoxy-11β,21-dihydroxypregna-1,4,16-triene-3,20-dione |
| Other names |
Trenbolone Acetate
Finaplix Revalor TBA Tren A |
| Pronunciation | /ˈɛlɛvənˌbeɪtəˌtwɛntiˈwʌn daɪˈhaɪdrɒksiˌprɛgnəˈwʌn.fɔːrˌsɪksˈtiːnˌtraɪiːnˌθriːˌtwɛnti daɪˈoʊnˌtwɛntiˈwʌn ˈæsɪteɪt/ |
| Identifiers | |
| CAS Number | 1172-56-3 |
| Beilstein Reference | 2267283 |
| ChEBI | CHEBI:35003 |
| ChEMBL | CHEMBL1626057 |
| ChemSpider | 21566101 |
| DrugBank | DB01407 |
| ECHA InfoCard | 03addd09-3bdd-4f2c-83bc-8afbba6c9dc1 |
| EC Number | 1.1.1.146 |
| Gmelin Reference | 1079793 |
| KEGG | C14425 |
| MeSH | D004715 |
| PubChem CID | 162673 |
| RTECS number | RA0350000 |
| UNII | 9FQ10934G7 |
| UN number | UN2811 |
| CAS Number | 2626-18-2 |
| Beilstein Reference | Beilstein 2068237 |
| ChEBI | CHEBI:31349 |
| ChEMBL | CHEMBL2060818 |
| ChemSpider | 75700268 |
| DrugBank | DB14651 |
| ECHA InfoCard | 100.163.234 |
| EC Number | 1.1.1.146 |
| Gmelin Reference | 1381378 |
| KEGG | C16751 |
| MeSH | D004715 |
| PubChem CID | 54680661 |
| RTECS number | YQ9275000 |
| UNII | 9FY07P2E8F |
| UN number | UN number not assigned |
| CompTox Dashboard (EPA) | DTXSID6020625 |
| Properties | |
| Chemical formula | C25H30O6 |
| Molar mass | 412.468 g/mol |
| Appearance | White solid |
| Odor | Odorless |
| Density | 1.24 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | 2.13 |
| Acidity (pKa) | 12.66 |
| Basicity (pKb) | 6.28 |
| Refractive index (nD) | 1.587 |
| Dipole moment | 4.42 D |
| Chemical formula | C25H30O6 |
| Molar mass | 414.487 g/mol |
| Appearance | White to Off-White Solid |
| Odor | Odorless |
| Density | 1.21 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 1.82 |
| Vapor pressure | 3.6E-12 mmHg at 25°C |
| Acidity (pKa) | 12.55 |
| Basicity (pKb) | 7.45 |
| Magnetic susceptibility (χ) | -4.1e-6 cm³/mol |
| Refractive index (nD) | 1.586 |
| Viscosity | Viscous oil |
| Dipole moment | 5.82 Debye |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 295.3 J·mol⁻¹·K⁻¹ |
| Std molar entropy (S⦵298) | 579.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -875.2 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -8313.1 kJ/mol |
| Pharmacology | |
| ATC code | H02AB09 |
| ATC code | H02AB06 |
| Hazards | |
| Main hazards | H315, H319, H335 |
| GHS labelling | GHS05, GHS07 |
| Pictograms | GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | H315, H319, H335 |
| Precautionary statements | P261, P264, P272, P280, P302+P352, P305+P351+P338, P362+P364 |
| NFPA 704 (fire diamond) | NFPA 704: 2-1-0 |
| LD50 (median dose) | LD50 2170 mg/kg (rat, oral) |
| NIOSH | DN9956000 |
| PEL (Permissible) | PEL (Permissible)": Not established |
| REL (Recommended) | 50 mg |
| GHS labelling | GHS02,GHS07,GHS08 |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | H302, H315, H319, H335 |
| Precautionary statements | P210, P233, P240, P241, P242, P243, P260, P264, P271, P272, P273, P280, P284, P301+P310, P302+P352, P304+P340, P305+P351+P338, P308+P311, P311, P312, P321, P330, P333+P313, P337+P313, P362+P364, P370+P378, P403+P233, P403+P235, P405, P501 |
| Flash point | > 298.6 °C |
| LD50 (median dose) | LD50=1180mg/kg (rat, oral) |
| NIOSH | Not Listed |
| PEL (Permissible) | PEL (Permissible Exposure Limit) not established |
| REL (Recommended) | 30 mg |
| Related compounds | |
| Related compounds |
Cortisone acetate
Prednisolone acetate Hydrocortisone acetate Dexamethasone acetate Betamethasone acetate |
| Related compounds |
Cortisone acetate
Prednisolone acetate Hydrocortisone acetate Corticosterone acetate Dexamethasone acetate |